文献
J-GLOBAL ID:201802222078601090
整理番号:18A0493448
療法の持続期間は米国におけるルーチン臨床診療における再発性/難治性多発性骨髄腫の治療を受けた患者における生存率の改善と関連している【Powered by NICT】
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States
著者 (11件):
Hari Parameswaran
(Department of Medicine, Medical College of Wisconsin, Milwaukee, WI)
,
Romanus Dorothy
(Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA)
,
Palumbo Antonio
(Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA)
,
Luptakova Katarina
(Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA)
,
Rifkin Robert M.
(Rocky Mountain Cancer Centers, Denver, CO)
,
Tran Linh Mai
(University of California, Berkeley, CA)
,
Raju Aditya
(Xcenda, LLC, Palm Harbor, FL)
,
Farrelly Eileen
(Xcenda, LLC, Palm Harbor, FL)
,
Noga Stephen J.
(Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA)
,
Blazer Marlo
(Xcenda, LLC, Palm Harbor, FL)
,
Chari Ajai
(Icahn School of Medicine at Mount Sinai, New York, NY)
資料名:
Clinical Lymphoma Myeloma and Leukemia
(Clinical Lymphoma Myeloma and Leukemia)
巻:
18
号:
2
ページ:
152-160
発行年:
2018年
JST資料番号:
W3263A
ISSN:
2152-2650
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)